换一批摘要In recent years, immune checkpoint inhibitors (ICIs) have become an important treatment strategy for advanced gastric cancer. Immunotherapy has gradually transitioned from a later-line to a first-line treatment for advanced gastric cancer. Simultaneously, more and more researchers have begun to pay attention to whether immunotherapy can be used for resectable gastric cancer. The current use of ICIs in the neoadjuvant treatment of gastric cancer is still in its exploratory stage, with a number of clinical trials currently underway. However, the available data show good application prospects. This article reviewsthe research progress on ICIs in the neoadjuvant therapy for gastric cancer and evokes some unresolved problems.
更多相关知识
DOI
10.1007/s10330-022-0551-1
发布时间
2022-05-18（万方平台首次上网日期，不代表论文的发表时间）
- 浏览20
- 被引0
- 下载5
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
